TY - JOUR
T1 - The effect of anti-interleukin 2 monoclonal antibody treatment on the survival of rat cardiac allograft
AU - Sakagami, Kenichi
AU - Ohsaki, Toshihide
AU - Ohnishi, Tetsuya
AU - Saito, Shinya
AU - Matsuoka, Junji
AU - Orita, Kunzo
N1 - Funding Information:
We acknowledge with gratitude the excellent assistance of Drs. Junji Hamuro and Yoshiaki Hanzawa in conducting this study. This work was supported in part by Grant No. 62570569f rom the Japanese Ministry of Education, Science, and Culture.
Copyright:
Copyright 2014 Elsevier B.V., All rights reserved.
PY - 1989/3
Y1 - 1989/3
N2 - The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P < 0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.
AB - The effect of anti-interleukin 2 monoclonal antibody (anti-IL2 MoAb) and the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb were examined in heterotopic rat cardiac allografts. Mouse anti-human recombinant IL2 MoAb was obtained by the hybridoma technique. The anti-IL2 MoAb, termed 8H-10, was an IgG2a which inhibited IL2-driven [3H]TdR incorporation in cytolytic T lymphocyte line cells at a dilution of 26. 8H-10 was injected iv at a dose of 200 μg/day for 8 consecutive days, beginning on the day of transplantation. Hearts from F344 rats (RT11v1) were transplanted into ACI recipient rats (RT11v1). The mean survival time was 7.6 ± 0.8 days in untreated controls, 9.0 ± 1.2 days in additional controls treated with mouse anti-sheep red blood cell monoclonal antibody, and 25.3 ± 18.4 days in the anti-IL2 MoAb (8H-10)-treated group (P < 0.05). Furthermore, the accumulation of intravenously administered 125I-labeled anti-IL2 MoAb (8H-10) was specifically seen in the grafted heart. In conclusion, these results suggest that IL2 may play an important role in allograft rejection and that anti-IL2 MoAb may serve as a useful immunosuppressive agent in clinical transplantation.
UR - http://www.scopus.com/inward/record.url?scp=0024519190&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024519190&partnerID=8YFLogxK
U2 - 10.1016/0022-4804(89)90068-1
DO - 10.1016/0022-4804(89)90068-1
M3 - Article
C2 - 2646474
AN - SCOPUS:0024519190
VL - 46
SP - 262
EP - 266
JO - Journal of Surgical Research
JF - Journal of Surgical Research
SN - 0022-4804
IS - 3
ER -